Nanomechanical Signatures in Glioma Cells Depend on CD44 Distribution in IDH1 Wild-Type but Not in IDH1R132H Mutant Early-Passage Cultures

被引:2
|
作者
Shmelev, Mikhail E. [1 ]
Farniev, Vladislav M. [1 ]
Shved, Nikita A. [1 ,2 ]
Kumeiko, Vadim V. [1 ,2 ]
机构
[1] Far Eastern Fed Univ, Inst Life Sci & Biomed, Vladivostok 690922, Russia
[2] Russian Acad Sci, AV Zhirmunsky Natl Sci Ctr Marine Biol, Far Eastern Branch, Vladivostok 690041, Russia
基金
俄罗斯科学基金会;
关键词
glioma; AFM; nanomechanics; biomechanics; cell stiffness; CD44; malignancy; cell proliferation; primary cell cultures; IDH1; EXPRESSION; HYALURONAN; PLASTICITY; STIFFNESS; DYNAMICS; PATHWAY; LINES;
D O I
10.3390/ijms24044056
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Atomic force microscopy (AFM) recently burst into biomedicine, providing morphological and functional characteristics of cancer cells and their microenvironment responsible for tumor invasion and progression, although the novelty of this assay needs to coordinate the malignant profiles of patients' specimens to diagnostically valuable criteria. Applying high-resolution semi-contact AFM mapping on an extended number of cells, we analyzed the nanomechanical properties of glioma early-passage cell cultures with a different IDH1 R132H mutation status. Each cell culture was additionally clustered on CD44+/- cells to find possible nanomechanical signatures that differentiate cell phenotypes varying in proliferative activity and the characteristic surface marker. IDH1 R132H mutant cells compared to IDH1 wild-type ones (IDH1wt) characterized by two-fold increased stiffness and 1.5-fold elasticity modulus. CD44+/IDH1wt cells were two-fold more rigid and much stiffer than CD44-/IDH1wt ones. In contrast to IDH1 wild-type cells, CD44+/IDH1 R132H and CD44-/IDH1 R132H did not exhibit nanomechanical signatures providing statistically valuable differentiation of these subpopulations. The median stiffness depends on glioma cell types and decreases according to the following manner: IDH1 R132H mt (4.7 mN/m), CD44+/IDH1wt (3.7 mN/m), CD44-/IDH1wt (2.5 mN/m). This indicates that the quantitative nanomechanical mapping would be a promising assay for the quick cell population analysis suitable for detailed diagnostics and personalized treatment of glioma forms.
引用
收藏
页数:16
相关论文
共 29 条
  • [1] Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma
    Sun, Chao
    Xiao, Liming
    Zhao, Yuanlin
    Shi, Jiankuan
    Yuan, Yuan
    Gu, Yu
    Zhang, Feng
    Gao, Xing
    Yang, Ying
    Yang, Risheng
    Qin, Junhui
    Zhang, Jin
    Wang, Chao
    Wang, Yingmei
    Wang, Zhe
    Hu, Peizhen
    Chang, Ting
    Wang, Liang
    Wang, Gang
    Chen, Huangtao
    Li, Zhuyi
    Ye, Jing
    TRANSLATIONAL ONCOLOGY, 2020, 13 (04):
  • [2] THE KETOGENIC DIET IS INEFFECTIVE IN PRECLINICAL MODELS OF IDH1 WILD-TYPE AND IDH1 MUTANT GLIOMA
    Javier, Rodrigo
    Horbinski, Craig
    NEURO-ONCOLOGY, 2021, 23 : 208 - 208
  • [3] The Ketogenic Diet is Ineffective in Preclinical Models of IDH1 Wild-type and IDH1 Mutant Glioma
    Horbinski, Craig
    Javier, Rodrigo
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2021, 80 (06): : 563 - 563
  • [4] Comparison of Transcriptomic Analysis between IDH1 Mutant and Wild-type of Lower Grade Glioma
    Lee, MinWook
    Jin, Hoeyoung
    Kim, Suwan
    Ji, SeonYeong
    Song, SeokJung
    Koh, DooHyun
    Choi, JoungWan
    Park, JeongMan
    Lee, YunGyeon
    Jo, GaeHoon
    Kim, JongIl
    Sim, JeongMin
    Ahn, JuWon
    Park, YoungJoon
    Kwack, KyuBum
    FASEB JOURNAL, 2020, 34
  • [5] Spontaneous In Vitro Senescence of Glioma Cells Confirmed by an Antibody Against IDH1R132H
    Stoczynsica-Fidelus, Ewelina
    Och, Waldemar
    Rieske, Piotr
    Bienkowski, Michal
    Banaszczyk, Mateusz
    Winiecka-Klimek, Marta
    Zieba, Jolanta
    Janik, Karolina
    Rosiak, Kamila
    Treda, Cezary
    Stawski, Robert
    Radomiak-Zaluska, Anna
    Piaskowski, Sylwester
    ANTICANCER RESEARCH, 2014, 34 (06) : 2859 - 2867
  • [6] IDH1 R132H Mutant Glioma and Its Compensatory Mechanisms for Maintaining Telomeres
    Si-Xiang, Yan
    Yi-Fan, Li
    Yao, Li
    Yi-Xuan, Li
    Xiang-Xiu, Li
    Jin-Kai, Tong
    Shu-Ting, Jia
    Ju-Hua, Dan
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2024, 51 (11) : 2845 - 2852
  • [7] SYNTHETIC LETHAL INTERACTIONS WITH IDH1R132H IN GLIOMA STEM-LIKE CELLS
    Ventosa, Maria
    Kadiyala, Padma
    Carney, Stephen
    Castro, Maria
    Lowenstein, Pedro
    NEURO-ONCOLOGY, 2019, 21 : 104 - 104
  • [8] MUTANT (R132H) IDH1-DRIVEN CELLULAR TRANSFORMATION MAKES CELLS DEPENDENT ON CONTINUED WILD TYPE IDH1 EXPRESSION IN A MODEL OF IN VITRO GLIOMAGENESIS
    Johannessen, T.
    Mukherjee, J.
    Wood, M.
    Viswanath, P.
    Ohba, S.
    Ronen, S.
    Berkvig, R.
    Pieper, R.
    NEURO-ONCOLOGY, 2017, 19 : 29 - 30
  • [9] Characterization of the oncogenic properties of mutant isocitrate dehydrogenase 1 (IDH1R132H) in human primary cells
    Barradas, M.
    Diezma, L.
    Perez-Ferreiro, C. M.
    Cerezo, A.
    Lospitao, E.
    Peregrina, S.
    Jimenez, S.
    Brooks, N. A.
    Torres, R.
    Geeganage, S.
    Gilmour, R.
    Velasco-Miguel, S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 128 - 129
  • [10] ATRXLoss and IDH1R132H impair self-renewal of glioma stem cells after proton radiotherapy.
    Garces, Angel Adrian
    Bronk, Lawrence
    Bhat, Krishna P.
    Grosshans, David R.
    CANCER RESEARCH, 2021, 81 (13)